Loading...
9th Antibody Industrial Symposium 2021 June 22 - 25 2021 | DIGITAL
News Twitter

PROGRAMME

schedule & speakers

Day 1

Tuesday, June 22nd 2021

9h15

Welcome address

9h30

OPENING KEYNOTE LECTURE

ATMP manufacturing process : key steps and challenges of the industrialization
SERVIER Hélène NEGRE

Hélène NEGRE
CMC Project Leader
SERVIER, France

10h15

Track New Engineering Approaches for the Next-generation of Therapeutic Antibodies and Alternative Fusion Formats

Support by SFI Antibody Club Antibody Club

Session I

Immunotherapy Drug Development characterization tools: From reporter assays to primary cell-based approaches and immunoassays
Promega Bénédicte Gagny

Bénédicte Gagny
Product Manager, Cell-Based Assay, Proteomic and tools for biologics characterization
Promega, France

Therapeutic antibody engineering to improve drugability
GenScript ProBio, China Li Chen

Li Chen
Associate Director of Biologics Discovery
GenScript ProBio, China

Lava Therapeutics Paul Parren

Paul Parren
Executive VP and Head of R&D
Lava Therapeutics, Netherlands

Synthetic human antibody library design and selection by coupling phage and mammalian cell display
Inserm Pierre Martineau

Pierre Martineau
Team Leader
Functional Screening and Targeting in Cancer Unit, Inserm
Deputy Director
Institut de Recherche en Cancérologie de Montpellier (IRCM), Université de Montpellier
Founder
Mabqi, France

HexElect technology: mutually dependent therapeutic IgG antibody combinations that act as Bio-Logic AND gates
Genmab Rob de Jong

Rob de Jong
Director, Antibody Format Development Lead
Genmab, Netherlands

Track Adoptive Cell Therapy : Latest Advancements

Session I

Use of antibodies for immune profiling: the Beckman Coulter experience
Beckman Coulter Anis Larbi

Anis Larbi
Field Marketing Western Europe
Beckman Coulter

CAR-T cell therapy: challenges and opportunities
Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Spain Sonia Guedan

Sonia Guedan
Junior Investigator
Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Spain

CAR T-Cell Immunotherapy of Solid Tumours: Parallel Learning from the Clinic and Lab
Leucid Bio John Maher

John Maher
Consultant & Senior Lecturer, Immunology
King's College London, UK
Scientific Founder & CSO
Leucid Bio

Genome editing of T Cells for cancer immunotherapy
Università Vita-Salute San Raffaele Chiara Bonini

Chiara Bonini
Deputy Director, Division of Immunology, Transplantation and Infectious Diseases
Group leader, Experimental hematology Unit
Full professor
Università Vita-Salute San Raffaele, Italy

12h00

Lunch Break– Partnering (B2B Virtual Meetings)

14h00

Track New Engineering Approaches for the Next-generation of Therapeutic Antibodies and Alternative Fusion Formats

Support by SFI Antibody Club Antibody Club

Session II

NK cell engagers
Innate Pharma, France Eric Vivier

Eric Vivier
Professor of Immunology
Aix-Marseille University & Public Hospital of Marseille, France
Scientific Director
Innate Pharma, France

Affinity-optimization of B7H6 for NK cell redirection
Merck KGaA, Germany Stefan Zielonka

Stefan Zielonka
Associate Director, Protein Engineering & Antibody Technologies
Merck KGaA, Germany

Oral IgA-based immunotherapy elicits local growth control of colorectal adenocarcinoma
B Cell Design Armelle Cuvillier

Armelle Cuvillier
Chairman, CSO
B Cell Design

Designer DNA Nanoarchitectures for Immunoengineering
George Mason University Rémi Veneziano

Rémi Veneziano
Assistant Professor of Bioengineering
George Mason University, Volgenau School of Engineering, Manassas VA, USA

Track Adoptive Cell Therapy : Latest Advancements

Session II

Enhancing CAR T-cell therapies with precision genome engineering
Cellectis Laurent Poirot

Laurent Poirot
SVP Immunology Division
Cellectis, France/USA

CELLTuneTM technology to improve immune cell therapies potency and safety
Honing Bioscience Zelia Gouveia

Zelia Gouveia
Senior Scientist and projects manager
Honing Bioscience, France

The development of Vdelta1 Gamma Delta T cell platforms for use in next generation allogeneic CAR therapies
GammaDelta Therapeutics Oliver Nussbaumer

Oliver Nussbaumer
Founder and Vice President
Immunology at GammaDelta Therapeutics, United Kingdom

Genetic engineering of hybridoma to improve functionality
Établissement Français du Sang Yannic Danger

Yannic Danger
Research Engineer
Établissement Français du Sang, France

Keep an eye on your target - Why increasing the half-life of your antibody is not always the solution
LYo-X GmbH Lionel Renaud

Lionel Renaud
Systems Pharmacology Modeler
LYo-X GmbH

16h00

Pitch Session : Innovative Approaches to detect and fight Diseases

Call for Abstracts ends April 30th 2021

VAST: a novel and versatile vaccination platform that induces robust and durable antibody responses
German Cancer Research Center Paraskevi-Maria Vlachou-Efstathiou

Paraskevi-Maria Vlachou-Efstathiou
Research Scientist, DKFZ
German Cancer Research Center, Germany

KisoBody: Development and pre-clinical assessment of a novel multispecific antibody platform
KisoJi Biotechnology Inc. Richard Wargachuk

Richard Wargachuk
Research Scientist
KisoJi Biotechnology Inc., Canada

Anti-tumoral and immunomodulatory activity of anti-cathepsin D-targeting antibody in mammary cancer in immunocompetent mouse models
IRCM Timothée David

Timothée David
PhD student
Institut de Recherche en Cancérologie de Montpellier (IRCM), France

Antitumor effects by combination of BC-PIV and TNFRSF ligands.
BioComo Inc. Masayuki Fukumura

Masayuki Fukumura
CEO
BioComo Inc., Japan

Hight throughput single cell clone selection
MicroOmiX Alain Wagner

Alain Wagner
CSO
MicroOmiX, France

Does STING in cancer cell sensitize to anti-PD1 immunotherapy?
IRCM Chiara Ursino

Chiara Ursino
PhD student
Institut de Recherche en Cancerologie de Montpellier, France

XtenCHO™, a new high-performance system for the transient expression of biotherapeutics
ProteoGenix Cyrille Megel

Cyrille Megel
Business Developer
ProteoGenix, France

Selection and optimization of nanobodies against BMPR2
Hybrigenics Services SAS Jean-Christophe Rain

Jean-Christophe Rain
CEO
Hybrigenics Services SAS, France

IMGT Approach for the Prediction of Epitope and Paratope Interaction
CNRS Anjana Kushwaha

Anjana Kushwaha
Study Engineer
IMGT, IGH, CNRS, France

Track Enhancing Immunotherapy Efficacy and Safety : New Preclinical Models

Specificity screening of biotherapeutics against extensive libraries of plasma membrane and secreted protein targets
Retrogenix Limited, UK Diogo Rodrigues Ferreirinha

Diogo Rodrigues Ferreirinha
European Business Development Manager
Retrogenix Limited, UK

Humanized mouse models to profile CAR T-cell toxicity and efficacy
IRCCS San Raffaele Scientific Institut, Italy Monica Casucci

Monica Casucci
Group Leader, Innovative Immunotherapies Unit
IRCCS San Raffaele Scientific Institut, Italy

Novel Organoid Models for Drug Development
Hubrecht Organoid Technology (HUB), Netherlands Robert Vries

Robert Vries
CEO
Hubrecht Organoid Technology (HUB), Netherlands

Modelling cellular microenvironment dynamics in 3D
iBET Catarina Brito

Catarina Brito
Head of the Advanced Cell Models Laboratory of the Animal Cell Technology Unit
iBET and ITQB-NOVA, Portugal

17h30

Partnering (B2B Virtual Meetings)

19h00

End of DAY 1

Day 2

Wednesday, June 23rd 2021

9h30

OPENING KEYNOTE LECTURE

Antibody–Drug Conjugates: The Last Decade
GICC, University of Tours, France Nicolas Joubert

Nicolas Joubert
Associate-Professor
GICC, University of Tours, France

10h15

Track New trends in ADCs Development

Towards more hydrophilic and better tolerated Antibody-Drug Conjugates (ADC)
Mablink Warren Viricel

Warren Viricel
Chief Scientific Officer
Mablink, France

Linker Matters: Highly Stable and Efficient ADCs Made with Native Antibodies and Peptide Linkers
Araris Biotech AG Philipp Spycher

Philipp Spycher
CEO
Araris Biotech AG, Switzerland

Combining Antibody-Drug Conjugates and Immune Checkpoint blockade therapy to restore tumor specific immunological response
Centre Leon Berard, Inserm UA8, France Sandrine Valsesia-Wittmann

Sandrine Valsesia-Wittmann
Senior Scientist in immuno-oncology and combinations therapies
Centre Leon Berard, Inserm UA8, France

Track Artificial Intelligence Tools to accelerate Drug Discovery

Session Sponsored by MabSilico

AI: the revolution in antibody discovery
INRA Anne Poupon

Anne Poupon
Senior Scientist
INRA, France

Antibody design, with a little help of my AI friend
Sanofi, France Hervé Minoux

Hervé Minoux
Associate Director of Data Science: in silico Drug Design
Sanofi, France

AI: the revolution in antibody discovery
MAbSilico Vincent Puard

Vincent Puard
CEO - Co-founder
MAbSilico, France

Ose immunotherapeutics Nicolas Poirier

Nicolas Poirier
Chief Scientific Officer
Ose immunotherapeutics

12h00

Lunch Break– Partnering (B2B Virtual Meetings)

14h00

Track Intellectual Property - Patenting antibodies : lessons learnt from recent court decisions

Session Sponsored by Regimbeau

Protecting epitope versus paratope: Case study from Amgen PCSK9
REGIMBEAU Raphaëlle Gillet

Raphaëlle Gillet
European & French Patent Attorney
REGIMBEAU, France

REGIMBEAU Nicolas Bouquin

Nicolas Bouquin
Senior Associate, European & French Patent Attorney
REGIMBEAU, France

How to Successfully be granted Patents of Fc regions of Therapeutic Antibodies in Japan (with Case Study of Chugai’s SMART-Ig® (Sweeping Antibody®))
SK IP Law Firm Akihiko Okuno

Akihiko Okuno
Managing Partner (Japanese Patent Attorney, Specific IP Litigation Attorney)
SK IP Law Firm, Japan

Overview of recent court decisions concerning antibody patents
Michalski Hüttermann & Partner Christoph Volpers

Christoph Volpers
European Patent Attorney
Michalski Hüttermann & Partner, Germany

PANEL OF DISCUSSION

Track mAbs against COVID-19 Pandemic

Development of polyclonal neutralizing antibodies against SARS-CoV-2
Xenothera, France Bernard Vanhove

Bernard Vanhove
CSO & COO
Xenothera, France

Monoclonal antibody blocking SARS-CoV-2 infection
University Utrecht, Netherlands Berend Jan Bosch

Berend Jan Bosch
Associate Professor
University Utrecht, Netherlands

Self-administered, Inhaled Human mAbs with Broad SARS-CoV2 Neutralization Activity
ARIDIS Pharmaceutical, USA Vu Truong

Vu Truong
CEO
ARIDIS Pharmaceutical, USA

Combined Single-cell Dispensing and 3D Full Well Imaging for Cell Lines with >99.99% Probability of Monoclonality
CYTENA Adrian Zambrano

Adrian Zambrano
Senior Field Application Specialist
CYTENA

Generation of Functional Monoclonal Antibodies by Single B Cell Cloning
Sino Biological Jiahui Yang

Jiahui Yang
Director of R&D
Sino Biological, China

16h00

Live Poster Session

Call for Abstracts ends April 30th 2021

Track Targeting the brain with biologics drugs

Acoustically-mediated antibody delivery
Inserm UMR 1253 iBrain - Université de Tours Jean-Michel Escoffre

Jean-Michel Escoffre
Senior Researcher
Inserm UMR 1253 iBrain - Université de Tours

A novel CD38 Modulation using antibodies to tackle neurodegenerative diseases
Encefa Damien Toulorge

Damien Toulorge
CSO
Encefa, France

Targeting biologic drugs through the blood-brain barrier as IgG fusion proteins
UCLA, Los Angeles, CA, USA William M. Pardridge

William M. Pardridge, M.D
Distinguished Professor Emeritus
UCLA, Los Angeles, CA, USA

17h30

Announcement of Best Poster

17h40

Partnering (B2B Virtual Meetings)

19h00

End of DAY 2

Day 3

Thursday, June 24th 2021

9h30

OPENING KEYNOTE LECTURE

Structural variations in human IgG and functional Fc-receptor mediated consequences
Sanquin Research, Netherlands Gestur Vidarsson

Gestur Vidarsson
Head of Immunoglobulin Research
Sanquin Research, Netherlands

10h15

Track Driving Innovative Drugs into Clinical Success

Session I

In vitro assays to assess unwanted immunogenicity and killing capacity of biotherapeutics
ImmunXperts Sofie Pattijn

Sofie Pattijn
CTO & Co-founder
ImmunXperts, a Nexelis company, Belgium

Tumor localized activation of the 4-1BB pathway using Anticalin based bispecifics. PRS-343 (4-1BB-HER2): from concept to clinical activity
Pieris Pharmaceuticals Shane Olwill

Shane Olwill
Senior Vice President, Head of Translational Science
Pieris Pharmaceuticals, Germany

CD47 targeting bispecific antibodies for hematological and solid cancer
Light Chain Bioscience Nicolas Fischer

Nicolas Fischer
CEO
Light Chain Bioscience – Novimmune SA, Switzerland

ATOR-1017, a second generation 4-1BB antibody for treatment of solid tumors
Alligator Bioscience Peter Ellmark

Peter Ellmark
CSO
Alligator Bioscience, Sweden

In silico clinical trials Driving innovative drugs into clinical success
Novadiscovery François-Henri Boissel

François-Henri Boissel
CEO
Novadiscovery (Clinical trial simulation), France

Track Improving Developability & CMC of biotherapies

Session I

Full Characterisation of Biologics - Process Development and Optimization for Best Process Economics
SARTORIUS Helge Schnerr

Helge Schnerr
Global Marketing
Sartorius, Germany

How to Control Glycosylation using In Vitro Glycoengineering
Roche Mathieu Thomas

Mathieu Thomas
International Alliance Manager
Roche

Immunogenicity of biopharmaceuticals: a role for protein aggregates?
Université Paris-Saclay, UMR-S 996 -Inserm/UPSaclay, France Marc Pallardy

Marc Pallardy
Professor, Director of Research
Université Paris-Saclay, UMR-S 996 -Inserm/UPSaclay, France

Challenges of Controlling High Mannose-Type N-Glycans in Therapeutic mAbs
Merck, Italy Horst Bierau

Horst Bierau
Senior Scientific Advisor – Head CMC Science & Intelligence
Merck, Italy

Advances in MS-Based Characterization Workflows and Case Studies from a Biopharmaceutical Development Lab
Symphogen Dan Bach Kristensen

Dan Bach Kristensen
Principal Scientist
Symphogen, a Servier Company, Denmark

12h30

Lunch Break– Partnering (B2B Virtual Meetings)

14h00

Track Driving Innovative Drugs into Clinical Success

Session II

Antibody-armed oncolytic viruses to address immuno-suppressed tumors
Transgene, France Eric Quéméneur

Eric Quéméneur
Executive vice-president, CSO
Transgene, France

Amanitin-based Antibody-Drug-Conjugates as New Therapeutic Modalities for Cancer Therapy
Heidelberg Pharma AG, Germany Andreas Pahl

Andreas Pahl
CSO
Heidelberg Pharma AG, Germany

IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
ImmunoGen Patrick Zweidler-McKay

Patrick Zweidler-McKay
Senior Medical Director for Hematologic and Solid Tumors
ImmunoGen, USA

Accelerating Drug Discovery with Twist Biopharma
Twist Bioscience, USA Qiang Liu

Qiang Liu
Director of Antibody Engineering
Twist Bioscience, USA

ZooMAb® Antibodies - a Novel Recombinant Technology
MERCK Wayne Speckmann

Wayne Speckmann
Head of Antibody Development
MERCK, USA

Track Improving Developability & CMC of biotherapies

Session II

Production of gene therapy vectors: CMC perspectives and challenges
Yposkesi Brian Mullan

Brian Mullan
Head, Process and Analytical Development, Cell and Gene Therapies
Yposkesi, France

State-of-the Art MS Methods for Characterizing mAbs, ADCs, BsAbs & fusion proteins
Centre d’Immunologie Pierre Fabre, France Alain Beck

Alain Beck
Senior Director, Biologics CMC & developability
Centre d’Immunologie Pierre Fabre, France

Novel Solution For High Throughput Antibody And Protein Purification Using Magnetic Beads
GenScript USA Nishant Saxena

Nishant Saxena
Product Manager, Protein Purification
GenScript USA

16h00

Closing Keynote

Antibodies to watch in 2021: Mid-year update
The Antibody Society Janice Reichert

Janice Reichert
Editor-in-Chief
mAbs
Executive Director
The Antibody Society
Managing Director
Reichert Biotechnology Consulting LLC, USA

16h40

Announcement of AIS2022

16h50

Partnering (B2B Virtual Meetings)

19h00

End of DAY 3

Day 4

Friday, June 25th 2021

9h00

Partnering (B2B Virtual Meetings)

12h00

Lunch Break

14h00

Partnering (B2B Virtual Meetings)

19h00

End of Congress

Organization contact
Ana Antunes
17 rue Crépet
69007 Lyon
+33 (0)4 78 02 39 91
ana-sofia.antunes@mabdesign.fr